RRC ID 77307
Author Li C, Wang H, Georgakopoulou A, Gil S, Yannaki E, Lieber A.
Title In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
Journal Mol Ther
Abstract We have recently reported that, after in vivo hematopoietic stem cell/progenitor (HSPC) transduction with HDAd5/35++ vectors, SB100x transposase-mediated γ-globin gene addition achieved 10%-15% γ-globin of adult mouse globin, resulting in significant but incomplete phenotypic correction in a thalassemia intermedia mouse model. Furthermore, genome editing of a γ-globin repressor binding site within the γ-globin promoter by CRISPR-Cas9 results in efficient reactivation of endogenous γ-globin. Here, we aimed to combine these two mechanisms to obtain curative levels of γ-globin after in vivo HSPC transduction. We generated a HDAd5/35++ adenovirus vector (HDAd-combo) containing both modules and tested it in vitro and after in vivo HSPC transduction in healthy CD46/β-YAC mice and in a sickle cell disease mouse model (CD46/Townes). Compared to HDAd vectors containing either the γ-globin addition or the CRISPR-Cas9 reactivation units alone, in vivo HSC transduction of CD46/Townes mice with the HDAd-combo resulted in significantly higher γ-globin in red blood cells, reaching 30% of that of adult human α and βS chains and a complete phenotypic correction of sickle cell disease.
Volume 29(2)
Pages 822-837
Published 2021-2-3
DOI 10.1016/j.ymthe.2020.09.001
PII S1525-0016(20)30458-5
PMID 32949495
PMC PMC7854285
MeSH Adenoviridae / genetics* Anemia, Sickle Cell / genetics* Anemia, Sickle Cell / therapy* Animals Disease Models, Animal Genetic Therapy* / methods Genetic Vectors / genetics* Hematopoietic Stem Cell Transplantation* / methods Hematopoietic Stem Cells / metabolism* Humans Mice Transgenes
IF 8.986
Altmetric score
オルトメトリクス指標項目
The most frequently cited source X(Twitter)
Total number of mentions 17
Altmetric score changes over past 6months 0.0
Resource
Human and Animal Cells HUDEP-2(RCB4557)